|
US3882246A
(en)
|
1971-05-21 |
1975-05-06 |
Merck & Co Inc |
Treatment of skeletal muscle disorders with cyclobenzaprine
|
|
US4968507A
(en)
|
1984-06-20 |
1990-11-06 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
FR2635461B1
(fr)
|
1988-08-18 |
1992-01-17 |
Adir |
Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
SG47101A1
(en)
|
1992-07-31 |
1998-03-20 |
Us Bioscience |
Crystalline amifostine compositions and methods for the preparation and use of same
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6753006B1
(en)
|
1993-02-22 |
2004-06-22 |
American Bioscience, Inc. |
Paclitaxel-containing formulations
|
|
US6096331A
(en)
|
1993-02-22 |
2000-08-01 |
Vivorx Pharmaceuticals, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US5439686A
(en)
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
US6749868B1
(en)
|
1993-02-22 |
2004-06-15 |
American Bioscience, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
|
BR9405798A
(pt)
|
1993-02-22 |
1995-12-12 |
Vivorx Pharmaceuticals Inc |
Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
|
|
US5354566A
(en)
|
1993-06-02 |
1994-10-11 |
Kraft General Foods, Inc. |
Preparation of yeast-leavened dough crusts
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
|
US6649186B1
(en)
|
1996-09-20 |
2003-11-18 |
Ethypharm |
Effervescent granules and methods for their preparation
|
|
US20030077227A1
(en)
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
|
WO1999018937A1
(en)
|
1997-10-16 |
1999-04-22 |
Merck & Co., Inc. |
New cyclobenzaprine composition
|
|
DK1077683T3
(da)
|
1998-05-14 |
2003-03-31 |
Alza Corp |
Antidepressiv behandling
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US6267985B1
(en)
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
|
US7374779B2
(en)
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
WO2001012175A1
(en)
*
|
1999-08-13 |
2001-02-22 |
Vela Pharmaceuticals Inc. |
Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine
|
|
BR0013122A
(pt)
*
|
1999-08-13 |
2002-04-30 |
Vela Pharmaceuticals Inc |
Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
|
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
|
WO2001089476A1
(en)
|
2000-05-19 |
2001-11-29 |
Npd Llc |
Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
|
|
EP1441708B1
(en)
|
2001-11-05 |
2009-04-08 |
Krele Pharmaceuticals LLC |
Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
|
|
US7700561B2
(en)
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
US7105486B2
(en)
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
|
US7659253B2
(en)
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
CA2503381A1
(en)
|
2002-10-25 |
2004-05-13 |
Collegium Pharmaceutical, Inc. |
Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
|
|
CN103405405A
(zh)
|
2002-12-09 |
2013-11-27 |
阿布拉西斯生物科学有限责任公司 |
组合物和传递药剂的方法
|
|
US8688385B2
(en)
|
2003-02-20 |
2014-04-01 |
Mayo Foundation For Medical Education And Research |
Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
|
|
US20050059656A1
(en)
|
2003-04-07 |
2005-03-17 |
Cornell Research Foundation, Inc. |
Compositions and methods for protecting against mitochondria component-mediated pathology
|
|
MXPA05012850A
(es)
|
2003-05-29 |
2006-05-17 |
New River Pharmaceuticals Inc |
Compuestos de anfetamina resistentes al abuso.
|
|
BRPI0415683A
(pt)
|
2003-11-03 |
2006-12-19 |
Warner Lambert Co |
inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
|
|
US20050143350A1
(en)
*
|
2003-11-19 |
2005-06-30 |
Seed John C. |
Combination drug therapy to treat obesity
|
|
CA2548281C
(en)
|
2003-12-09 |
2013-11-12 |
Medcrystalforms, Llc |
Method of preparation of mixed phase co-crystals with active agents
|
|
JP5179757B2
(ja)
|
2004-02-17 |
2013-04-10 |
トランセプト ファーマシューティカルズ， インコーポレイティド |
口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
|
|
TW200531680A
(en)
|
2004-03-03 |
2005-10-01 |
Merz Pharma Gmbh & Co Kgaa |
Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
|
|
US8216610B2
(en)
|
2004-05-28 |
2012-07-10 |
Imaginot Pty Ltd. |
Oral paracetamol formulations
|
|
US20070196364A1
(en)
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
|
US7532935B2
(en)
|
2005-07-29 |
2009-05-12 |
Cyberonics, Inc. |
Selective neurostimulation for treating mood disorders
|
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
US20090069267A1
(en)
|
2006-01-17 |
2009-03-12 |
Abrams Daniel J |
Central administration of stable formulations of therapeutic agents for cns conditions
|
|
US20080146672A1
(en)
|
2006-12-08 |
2008-06-19 |
Denton Marcia Marye |
Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
|
|
EP2514417A3
(en)
|
2007-05-07 |
2013-01-30 |
Chelsea Therapeutics, Inc. |
Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
|
|
CA2690737A1
(en)
|
2007-06-22 |
2008-12-31 |
Merck Sharp & Dohme Corp. |
6.5-pyrrolopiperidine tachykinin receptor antagonists
|
|
JP2010534676A
(ja)
|
2007-07-23 |
2010-11-11 |
シノシア・セラピューティクス |
心的外傷後ストレス障害の治療
|
|
US20090060983A1
(en)
|
2007-08-30 |
2009-03-05 |
Bunick Frank J |
Method And Composition For Making An Orally Disintegrating Dosage Form
|
|
SI2200588T1
(sl)
|
2007-09-25 |
2019-08-30 |
Solubest Ltd. |
Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
|
|
EP2203158A4
(en)
|
2007-10-30 |
2012-12-26 |
Reddys Lab Ltd Dr |
PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
|
|
US20090148532A1
(en)
|
2007-12-06 |
2009-06-11 |
Venkatesh Gopi M |
Preparation of controlled release skeletal muscle relaxant dosage forms
|
|
ES2620672T3
(es)
|
2008-01-09 |
2017-06-29 |
Charleston Laboratories, Inc. |
Comprimidos de doble capa que comprenden oxicodona y prometazina
|
|
WO2009100222A1
(en)
|
2008-02-08 |
2009-08-13 |
Qps Llc |
Non-polymeric compositions for controlled drug delivery
|
|
US9314469B2
(en)
|
2008-05-05 |
2016-04-19 |
Tonix Pharma Holdings Limited |
Method for treating neurocognitive dysfunction
|
|
JP5380909B2
(ja)
|
2008-05-30 |
2014-01-08 |
株式会社ブリヂストン |
金型及び樹脂発泡成形品の成形方法
|
|
US20100266682A1
(en)
|
2008-12-10 |
2010-10-21 |
Nipun Davar |
Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
|
|
US20100247586A1
(en)
|
2009-03-27 |
2010-09-30 |
Andreas Hugerth |
Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
|
|
EP2233134A1
(en)
|
2009-03-27 |
2010-09-29 |
McNeil AB |
Multi-portion intra-oral dosage form with organoleptic properties
|
|
US8871263B2
(en)
|
2009-09-24 |
2014-10-28 |
Mcneil-Ppc, Inc. |
Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
|
|
HRP20171739T1
(hr)
|
2009-11-20 |
2018-03-09 |
Tonix Pharma Holdings Limited |
Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
|
|
US20110319389A1
(en)
|
2010-06-24 |
2011-12-29 |
Tonix Pharmaceuticals, Inc. |
Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
|
|
WO2012050594A1
(en)
|
2010-09-01 |
2012-04-19 |
Tonix Pharmaceuticals, Inc. |
Treatment for cocaine addiction
|
|
US11998516B2
(en)
|
2011-03-07 |
2024-06-04 |
Tonix Pharma Holdings Limited |
Methods and compositions for treating depression using cyclobenzaprine
|
|
ITMI20110558A1
(it)
|
2011-04-06 |
2012-10-07 |
Campiglio Consulting Srl |
Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
|
|
SMT202200436T1
(it)
|
2012-06-15 |
2023-01-13 |
Tonix Pharma Holdings Ltd |
Composizioni e metodi per l’assorbimento transmucosale
|
|
JP6479670B2
(ja)
|
2012-11-05 |
2019-03-06 |
エモリー ユニバーシティー |
７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
|
|
JP6310542B2
(ja)
|
2013-03-15 |
2018-04-11 |
トニックス ファーマシューティカルズ， インコーポレイテッド |
シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤
|
|
US20160015818A1
(en)
|
2014-07-18 |
2016-01-21 |
Medipath, Inc. |
Compositions and methods for physiological delivery using cannabidiol
|
|
SG11201701995PA
(en)
|
2014-09-18 |
2017-04-27 |
Tonix Pharma Holdings Ltd |
Eutectic formulations of cyclobenzaprine hydrochloride
|
|
US11826321B2
(en)
|
2017-12-11 |
2023-11-28 |
Tonix Pharma Holdings Limited |
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
|
|
WO2023250036A1
(en)
|
2022-06-21 |
2023-12-28 |
Tonix Pharmaceuticals Holding Corp. |
Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
|